Literature DB >> 23608655

Endothelin, kidney disease, and hypertension.

Joshua S Speed1, David M Pollock.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23608655      PMCID: PMC3804114          DOI: 10.1161/HYPERTENSIONAHA.113.00595

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


× No keyword cloud information.
  47 in total

1.  Ambrisentan and tadalafil synergistically relax endothelin-induced contraction of rat pulmonary arteries.

Authors:  Faquan Liang; Suya Yang; Lina Yao; Luiz Belardinelli; John Shryock
Journal:  Hypertension       Date:  2012-02-06       Impact factor: 10.190

2.  Chronic selective endothelin A receptor antagonism reduces serum uric acid in hypertensive chronic kidney disease.

Authors:  Neeraj Dhaun; Neil R Johnston; Jane Goddard; David J Webb
Journal:  Hypertension       Date:  2011-06-27       Impact factor: 10.190

3.  The vascular endothelial growth factor receptor inhibitor sunitinib causes a preeclampsia-like syndrome with activation of the endothelin system.

Authors:  Mariëtte H W Kappers; Frank M M Smedts; Thomas Horn; Joep H M van Esch; Stefan Sleijfer; Frank Leijten; Sebastiaan Wesseling; Helena Strevens; A H Jan Danser; Anton H van den Meiracker
Journal:  Hypertension       Date:  2011-06-13       Impact factor: 10.190

4.  Renal medullary endothelin-1 is decreased in Dahl salt-sensitive rats.

Authors:  Joshua S Speed; Babbette LaMarca; Hunter Berry; Kathy Cockrell; Eric M George; Joey P Granger
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-05-25       Impact factor: 3.619

5.  Endothelin 1 activation of endothelin A receptor/NADPH oxidase pathway and diminished antioxidants critically contribute to endothelial progenitor cell reduction and dysfunction in salt-sensitive hypertension.

Authors:  Dan-Dan Chen; Yu-Gang Dong; Hong Yuan; Alex F Chen
Journal:  Hypertension       Date:  2012-03-19       Impact factor: 10.190

6.  Calcitonin gene-related peptide terminates long-lasting vasopressor responses to endothelin 1 in vivo.

Authors:  Merlijn J P M T Meens; Nadine J A Mattheij; Jelly Nelissen; Pieter Lemkens; Matthijs G Compeer; Ben J A Janssen; Jo G R De Mey
Journal:  Hypertension       Date:  2011-05-23       Impact factor: 10.190

7.  Sunitinib-induced systemic vasoconstriction in swine is endothelin mediated and does not involve nitric oxide or oxidative stress.

Authors:  Mariëtte H W Kappers; Vincent J de Beer; Zhichao Zhou; A H Jan Danser; Stefan Sleijfer; Dirk J Duncker; Anton H van den Meiracker; Daphne Merkus
Journal:  Hypertension       Date:  2011-11-28       Impact factor: 10.190

8.  Endothelin type A receptor antagonist attenuates placental ischemia-induced hypertension and uterine vascular resistance.

Authors:  Kiran B Tam Tam; Eric George; Kathy Cockrell; Marietta Arany; Joshua Speed; James N Martin; Babbette Lamarca; Joey P Granger
Journal:  Am J Obstet Gynecol       Date:  2011-04       Impact factor: 8.661

9.  Oxidative stress contributes to sex differences in blood pressure in adult growth-restricted offspring.

Authors:  Norma B Ojeda; Bettye Sue Hennington; Danielle T Williamson; Melanie L Hill; Nicole E E Betson; Julio C Sartori-Valinotti; Jane F Reckelhoff; Thomas P Royals; Barbara T Alexander
Journal:  Hypertension       Date:  2012-05-14       Impact factor: 10.190

10.  Role of 20-hydroxyeicosatetraenoic acid in mediating hypertension in response to chronic renal medullary endothelin type B receptor blockade.

Authors:  Joshua S Speed; Eric M George; Marietta Arany; Kathy Cockrell; Joey P Granger
Journal:  PLoS One       Date:  2011-10-07       Impact factor: 3.240

View more
  30 in total

1.  Cre recombinase-regulated Endothelin1 transgenic mouse lines: novel tools for analysis of embryonic and adult disorders.

Authors:  Andre L P Tavares; David E Clouthier
Journal:  Dev Biol       Date:  2015-02-25       Impact factor: 3.582

Review 2.  Inhibition of ENaC by endothelin-1.

Authors:  Andrey Sorokin; Alexander Staruschenko
Journal:  Vitam Horm       Date:  2015-03-06       Impact factor: 3.421

3.  A Salt-Induced Reno-Cerebral Reflex Activates Renin-Angiotensin Systems and Promotes CKD Progression.

Authors:  Wei Cao; Aiqing Li; Liangliang Wang; Zhanmei Zhou; Zhengxiu Su; Wei Bin; Christopher S Wilcox; Fan Fan Hou
Journal:  J Am Soc Nephrol       Date:  2015-01-29       Impact factor: 10.121

4.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

5.  Endothelin antagonists in diabetic nephropathy: back to basics.

Authors:  Kiran Chandrashekar; Luis A Juncos
Journal:  J Am Soc Nephrol       Date:  2014-04-10       Impact factor: 10.121

Review 6.  Blood pressure and amiloride-sensitive sodium channels in vascular and renal cells.

Authors:  David G Warnock; Kristina Kusche-Vihrog; Antoine Tarjus; Shaohu Sheng; Hans Oberleithner; Thomas R Kleyman; Frederic Jaisser
Journal:  Nat Rev Nephrol       Date:  2014-01-14       Impact factor: 28.314

7.  Role of GRK4 in the regulation of the renal ETB receptor in hypertension.

Authors:  Yang Yang; Meixiang Li; Xue Zou; Caiyu Chen; Shuo Zheng; Chunjiang Fu; Ken Chen; Pedro A Jose; Cong Lan; Yukai Liu
Journal:  FASEB J       Date:  2020-07-20       Impact factor: 5.191

8.  Elevated plasma endothelin-1 is associated with reduced weight loss post vertical sleeve gastrectomy.

Authors:  Haley N Jenkins; London J Williams; Adam Dungey; Kenneth D Vick; Bernadette E Grayson; Joshua S Speed
Journal:  Surg Obes Relat Dis       Date:  2019-04-09       Impact factor: 4.734

Review 9.  Cardiac Fibrosis: The Fibroblast Awakens.

Authors:  Joshua G Travers; Fadia A Kamal; Jeffrey Robbins; Katherine E Yutzey; Burns C Blaxall
Journal:  Circ Res       Date:  2016-03-18       Impact factor: 17.367

10.  Endothelin receptor polymorphisms in the cardiovascular system: potential implications for therapy and screening.

Authors:  Luise Holzhauser; Ronald Zolty
Journal:  Heart Fail Rev       Date:  2014-11       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.